Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Atopic dermatitis treatment sees promising future with new drug approvals, says GlobalData

Atopic dermatitis (AD) is experiencing a transformative shift in treatment management with recent drug approvals that address critical unmet needs. The introduction of novel therapies, such as Dermavant’s VTAMA (tapinarof) (Japan) and Arcutis’s ZORYVE (roflumilast) (US), with innovative mechanisms of action, offers hope for improved patient outcomes. As these treatments enter the market, they underscore […]
Read more

Eli Lilly obesity drug tirzepatide approval in China strengthens market position amid GLP-1 agonist competition, says GlobalData

Eli Lilly’s tirzepatide (Mounjaro) has recently been approved by the National Medical Products Administration (NMPA) for treating obesity. This approval, based on the positive results from the SURMOUNT-CN clinical trial, makes tirzepatide the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for obesity treatment in China, which is expected to […]
Read more

Viking Therapeutics’ obesity drug could become direct competitor to Eli Lilly’s tirzepatide, says GlobalData

The obesity market continues to expand, but therapeutic options remain limited and shortages in supply continue. This creates a significant opportunity for new entrants. Numerous companies are exploring potential breakthrough mechanisms of action beyond GLP-1R agonists, while others are focusing on the synergistic effects of targeting multiple receptors to enhance the benefits of GLP-1R agonists. […]
Read more

Zydus and Roche legal battle highlights need for affordable breast cancer treatments in India, says GlobalData

Zydus Life Sciences is engaged in a legal battle with Roche over its biosimilar, Sigrima, which is based on Roche’s Perjeta (Pertuzumab), targeting the human epidermal growth factor receptor 2-positive (HER2+) breast cancer market in India. As cases of HER2+ breast cancer rise in the country, the conflict underscores the critical need for cost-effective biosimilars […]
Read more

Sionna and AbbVie deal can redefine cystic fibrosis therapeutics, says GlobalData

Sionna Therapeutics, a US-based clinical-stage life sciences company specializing in cystic fibrosis (CF), has secured exclusive global rights to develop and commercialize multiple advanced compounds through a license agreement with AbbVie. This strategic acquisition includes Phase 2 compounds ABBV-2222 and ABBV-3067, and Phase 1 compound ABBV-2851, bolstering Sionna’s pipeline and its position in the CF […]
Read more

Gilead’s lenacapavir holds greater potential in reducing HIV incidence than currently marketed drugs, says GlobalData

At the 25th International AIDS Conference (AIDS 2024) that took place from July 22-26 in Munich, Germany, Gilead presented full efficacy and safety results for its Phase III PURPOSE 1 HIV prevention trial for lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor. Lenacapavir demonstrated zero infections and 100% efficacy, as well as superior prevention of HIV […]
Read more

Phase III post-marketing commitment study data paves way for usage of Paratek’s Nuzyra in other indications, says GlobalData

Paratek Pharmaceuticals has announced positive topline efficacy and safety data from a global, Phase III post-marketing commitment study of its novel antibiotic, a next-generation tetracycline, Nuzyra (omadacycline). In a study of 670 adults with moderate to severe community-acquired bacterial pneumonia (CABP), Nuzyra was found to be generally safe and well-tolerated. The drug met both primary […]
Read more

NewAmsterdam’s obicetrapib holds potential to become first CETP inhibitor to advance to clinical practice, says GlobalData

NewAmsterdam Pharma has completed the enrollment of 407 patients in the pivotal Phase III TANDEM clinical trial evaluating obicetrapib in combination with ezetimibe in patients with heterozygous familial hypercholesterolemia (HeFH) and/or atherosclerotic cardiovascular disease (ASCVD). Obicetrapib has demonstrated strong tolerability in more than 800 patients with elevated lipid levels in NewAmsterdam’s clinical trials to date. […]
Read more

Mabwell leads development of new generation nectin-4 ADCs in China for triple-negative breast cancer, says GlobalData

Mabwell (Shanghai) Bioscience recently received the National Medical Products Administration (NMPA) approval for its 9MW2821, a novel nectin-4 targeting ADC (antibody-drug conjugate), to enter Phase II clinical trial in China. The preliminary clinical results of the Phase I/II study presented at the 2024 American Society of Clinical Oncology (ASCO) annual meeting demonstrated promising efficacy in […]
Read more

SC0062 trial results highlight BioCity’s potential to differentiate in kidney disease space, says GlobalData

BioCity Biopharma recently announced positive results from the ongoing 2-SUCCEED trial. The use of SC0062 resulted in a clinically meaningful and statistically significant reduction in proteinuria in patients with immunoglobulin A (IgA) nephropathy (IgAN). The aging global population will lead to an increase in the prevalence of chronic kidney disease (CKD), leading to an expansion […]
Read more

Majority of UK physicians see continued rise in telemedicine usage, reveals GlobalData

The COVID-19 pandemic has significantly accelerated telemedicine adoption globally, with 76% of UK physicians* reporting increased usage post-pandemic. An overwhelming 89% of physicians expect further growth in telemedicine use, indicating strong confidence in the future expansion and integration of telemedicine into routine healthcare practices, according to GlobalData, a leading data and analytics company. GlobalData’s latest […]
Read more
1 … 17 18 19 20 21 … 110